keep Therapeutic Goods Amendment Regulations 2001 (No. 2)
Amendment to Therapeutic Goods Regulations addressing the supply, manufacture, import, export, and regulation of therapeutic goods (medicines, medical devices, biologicals) in Australia. Modifies compliance requirements, registration and listing processes, advertising rules, and TGA administrative powers under the Therapeutic Goods Act 1989.
Therapeutic goods regulations address genuine information asymmetries where consumers cannot independently verify medicine and medical device safety before use. Unlike many regulations that merely transfer wealth or create barriers without justification, therapeutic goods regulation serves a legitimate public health function. While the TGA regime could be streamlined and mutual recognition with comparable jurisdictions (e.g., EU, US FDA) should be pursued to reduce approval timelines and compliance costs, deletion would create a regulatory vacuum vulnerable to exploitation. Unsafe medicines or defective medical devices reaching consumers would cause direct harm and destroy confidence in Australia's healthcare and pharmaceutical export sectors. The compliance costs, while significant, are inherent to any functional therapeutic goods regulatory system and must be weighed against the alternative of unverified products reaching vulnerable patients.